ABSTRACT SUBMISSION


Abstract Submission Deadline: 10 February 2019

Submission Deadlines
Abstract submissions are now being accepted. Submit your work for consideration. Abstracts may only be submitted using the template on the conference’s abstract submission portal. For all accepted presentation, the presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission. Please note that the abstract content may be edited at the discretion of the Scientific Committee.
Opens: Monday, Oct 26, 2019 at 9:00 am (Turkish Time)
Closes: Sunday, Feb 10, 2019 at 11:59 pm (Turkish Time)

Abstracts received after this deadline will not be accepted.

Overview

Abstracts submitted will be reviewed by the Scientific Committee for potential presentation.  If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information. Abstracts may only be submitted using the template on the conference’s abstract submission portal. Abstracts submitted by fax or email will not be accepted. All abstracts must be submitted and presented in English. Please use US English spelling and have your abstract proofread for grammar and understanding. Please ensure that your abstract has never been presented before. If this rule is not respected, the abstract will be rejected and will not be considered for an AASLD – TASL Connect event. 

Abstract notification will be sent to presenting authors by mid-February.

HEADER FOR ACCORDION – Abstract Submission Guidelines
Title
The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.

Abstract Body
The body of the abstract needs to include:

  • A background
  • Description of methods
  • Summary of results obtained
  • Statement of conclusion reached


There is a set 3,000 maximum character count for the abstract body.

Attachments
You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB

Author Types
Only one presenting and corresponding author may be selected – see author definitions below

  • Co-Author – One of several authors who provided a significant contribution to the abstract.
  • Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
  • Presenting Author – The author who will be presenting the poster at the meeting.


The maximum number of authors on an abstract is 30.
Questions
For questions about the abstract submission process, please send an email to tasl@tasl.org.tr . After having submitted your abstract, you will receive a confirmation by e-mail. Should you wish to make corrections to an abstract already submitted please contact the TASL office – tasl@tasl.org.tr Corrections to abstracts can only be made up to the announced submission deadline.

If an abstract is accepted, one author must attend the conference and present it in person. Acceptance of the abstract implies payment of the registration fee by the presenting author.

HEADER FOR ACCORDION – Abstract Policies

Ethics Policy
The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD - TASL Connect meeting. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. AASLD-TASL Connect meeting will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Disclosure Policy
It is the policy of the AASLD and TASL to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD and TASL sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.
All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.